Shire, Bioverativ fall after Roche hemophilia A study hits goals

Shares of Shire (SHPG) and Bioverativ (BIVV) are lower after Roche's (RHHBY) Genentech unit said its Phase III 3 study evaluating Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII met its primary and key secondary endpoints. The study showed a statistically significant and clinically meaningful reduction in the number of treated bleeds over time in people receiving Hemlibra prophylaxis every week compared to those receiving no prophylaxis, Genentech announced earlier today in a statement. Following the news, shares of Shire are down 3% to $142.53 and Bioverativ (BIVV) is down 6% to $52.80 in pre-market trading.